Clinical Trial Update: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and preliminary activity of the CHK1 inhibitor prexasertib (LY2606368) in combination with cyclophosphamide or gemcitabine f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma
• Medulloblastoma Group
• Medulloblastoma Shh-subtype

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Gemcitabine (Gemcitabine)
• Prexasertib (LY2606368) (LY2606368)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Brain Tumor, Brain Tumor, Recurrent | Phase 1 | Status: COMPLETED